ARTICLE | Clinical News
Tcelna: Ph IIb Abili-T data
February 1, 2017 10:16 PM UTC
Last October, Opexa reported top-line data from the double-blind, North American Phase IIb Abili-T trial in 183 patients with SPMS showing that subcutaneous Tcelna missed the primary endpoint of reduc...
BCIQ Company Profiles
BCIQ Target Profiles